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Background: Stroke is one of the most relevant reasons of death and disability worldwide. Many cost of illness
studies have been performed to evaluate direct and indirect costs of ischaemic stroke, especially within the first
year after the acute episode, using different methodologies.
Methods: We conducted a longitudinal, retrospective, bottom-up cost of illness study, to evaluate clinical and
economic outcomes of a cohort of patients affected by a first cerebrovascular event, including subjects with
ischaemic, haemorrhagic or transient episodes. The analysis intended to detect direct costs, within 1, 2 and 3 years
from the index event. Clinical patient data collected in regional disease registry were integrated and linked to
regional administrative databases to perform the analysis.
Results: The analysis of costs within the first year from the index event included 800 patients. The majority of
patients (71.5%) were affected by ischaemic stroke. Overall, per patient costs were €7,079. Overall costs significantly
differ according to the type of stroke, with costs for haemorrhagic stroke and ischaemic stroke amounting to €9,044
and €7,289. Hospital costs, including inpatient rehabilitation, were driver of expenditure, accounting for 89.5% of
total costs. The multiple regression model showed that sex, level of physical disability and level of neurological
deficit predict direct healthcare costs within 1 year. The analysis at 2 and 3 years (per patient costs: €7,901 and
€8,874, respectively) showed that majority of costs are concentrated in the first months after the acute event.
Conclusions: This cost analysis highlights the importance to set up significant prevention programs to reduce the
economic burden of stroke, which is mostly attributable to hospital and inpatient rehabilitation costs immediately
after the acute episode. Although some limitation typical of retrospective analyses the approach of linking clinical
and administrative database is a power tool to obtain useful information for healthcare planning.
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The traditional definition of a stroke, [1], is “a neurological
deficit of cerebrovascular cause that persists beyond 24
hours or is interrupted by death within 24 hours”. World-
wide, stroke is one of the most common causes of death,
long-term morbidity and disability [2-4]. Annually, 15 mil-
lion people worldwide suffer a stroke [5]. Of these, 5 million
die and another 5 million are left permanently disabled, pla-
cing a burden on family and community. Moreover, due to
the progressive population ageing, the absolute number of* Correspondence: ebottacchi@ausl.vda.it
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reproduction in any medium, provided the orstroke incidence is expected to increase. By 2030, stroke
would be the leading cause of 10.4% and 11.8% of male and
female annual deaths, respectively [6].
Owing to the high level of morbidity associated with
stroke, the economic burden of this disease is substan-
tial. For 2008, it was estimated that stroke would cost
the US economy $ 65.5 billion in healthcare services,
medications, and lost productivity [7].
Stroke can be classified into two major categories: is-
chaemic and haemorrhagic. Ischaemic stroke is caused
by an interruption of the blood supply, while haemor-
rhagic stroke results from a rupture of a blood vessel or
an abnormal vascular structure. 87% of strokes areal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[8].
Many international [9-19] and national [20,21] stud-
ies have estimated healthcare costs and resource
utilization associated with ischaemic stroke, particularly
those costs and hospitalizations that arise from non-
stroke-related cardiovascular events in the post-stroke
follow-up period. Conversely, there is still poor infor-
mation on the economic burden of haemorrhagic
stroke.
Cost-of-illness (COI) analysis is the main method of
providing an overall view on the economic impact of a dis-
ease [22]. In Italy, two different studies have evaluated the
economic burden of stroke in Italy, using various
approaches. Gerzeli et al., in the ECLIPSE study [20], eval-
uated direct and indirect costs of stroke using a longitu-
dinal, incidence-based methodology. Morsanutto et al.
[21] estimated cost and outcomes after first stroke hospital
admission using administrative databases.
Region Valle d’Aosta owns a large informative system
on administrative patients’ claims, collecting records on
healthcare services offered to the resident population
(prescriptions, ambulatory interventions, hospitaliza-
tions). In the same timeframe the Regional Valle d’Aosta
Hospital has set up a stroke clinical registry, including
patients who have been hospitalized since 1 January
2004 to date. The main purpose of the present study is
to link the two clinical and administrative sources in
order to: 1) estimate the current burden of stroke in
Valle d’Aosta; 2) evaluate the risk of death and of further
hospitalization due to cardio-cerebrovascular reason; 3)
evaluate the annual costs of stroke comparing the costs
according to the type of cerebrovascular event; 4) assess
the contribute of each cost component on total annual
costs; 5) determine the relation between costs, demo-


















Figure 1 Structure of database linkage*.Methods
Study design
The present study is a longitudinal, retrospective,
bottom-up cost of illness study, aimed to evaluate clin-
ical and economic outcomes of a cohort of patients
affected by a first cerebrovascular event (stroke or tran-
sient ischaemic attack, TIA). The analysis is conducted
in the perspective of the Italian regional healthcare sys-
tem: only direct costs have been evaluated. In the main
analysis, patients who were hospitalized for a cerebro-
vascular accident, included in the disease clinical regis-
try, matching inclusion criteria, were observed up to 1
year after hospital admission or death, whichever came
first. The date of hospital admission was the index date
and coincided with the beginning of observation. Dates
of death and/or next hospitalizations due to cardio-
cerebrovascular event, if applicable, were detected
through record linkage between the clinical registry, the
demographic database and the hospitalization database,
respectively. Economic resources used by patients were
detected through record linkage between regional ad-
ministrative healthcare archives and the clinical registry
(Figure 1). Cerebrovascular-related resource consump-
tion data on hospitalizations, pharmaceutical prescrip-
tions, ambulatory interventions (also including patients’
rehabilitation), after index date were collected. Add-
itional analyses were performed to assess clinical out-
comes and costs over a period of two and three years.
Data sources
Data from different sources were integrated through data-
base linkage and then used to conduct the analysis: 1) data
included in the clinical disease registry; 2) administrative
data on demographic status of the Val d’Aosta resident
population; 3) data on pharmaceutical prescriptions; 4)





















Table 1 Reasons for exclusion criteria
Exclusion criteria* No. of patients excluded (%)
Index date not allowing a 365 days - observation period 362 (45.3%)
Previous major cerebrovascular event 272 (34.0%)
Venous trombo-embolism 1 (<1.0%)
Age < 18 years 1 (<1.0%)
* Patients can have more than one exclusion criteria at the same time.
Bottacchi et al. BMC Health Services Research 2012, 12:372 Page 3 of 11
http://www.biomedcentral.com/1472-6963/12/372hospitalizations. Data from datasets 1, 2, 4 and 5 covered
the period between January 1, 2004 and December 31,
2007. Data from dataset 3 covered the period between
January 1, 2003 and December 31, 2007.
As sensitive patients’ information was stored in data
sources, the present study was submitted to the Ethical
Committee of Aosta LHU, which approved it. Also, in
order to assure patients’ privacy, identification codes
used in both administrative databases and clinical
registries were preliminary transformed into alpha-
numeric codes, so that researches could not have ac-
cess to sensitive data.Inclusion and exclusion criteria
To be included in the analysis, subjects must be
recorded in the disease clinical registry, collecting all
hospital admissions due to cerebrovascular diseaseTable 2 Sample characteristics: demographic variables
Variable 800 (100%)
Total patients – No (%)
Sex – No. (%)
Male 389 (48.6%)
Female 411 (51.4%)
Class of age – No (%)
< 45 years 32 (4.0%)
45–64 years 120 (15.0%)
65–74 years 176 (22.0%)
75–84 years 309 (38.6%)
85 years 163 (20.4%)
Age, years – Mean (± SD) 74.9 (±13.5)
Job activity – No (%)
Total number of patients 795 (100%)
Housewife 22 (2.8%)
Not occupied 1 (<1.0%)
Retired 675 (84.0%)
Employed 97 (12.2%)
Life conditions – No (%)
Total number of patients 795 (100%)
Lives in community 39 (4.9%)
Lives alone 194 (24.4%)
Lives with others (family) 562 (70.7%)(confirmed stroke or TIA) occurred in the period
January 1, 2004, December 31, 2007. The following
subjects were excluded: 1) subjects with invalid demo-
graphic status at the index date (resulting as not resi-
dent or emigrated); 2) subjects who were not present
in the database of hospital records (invalid database
linkage); 3) subjects aged < 18 years; 4) subjects with
previous documented stroke; 4) subjects not potentially
observable for 1 year (index date after January 1,
2007). Patients with history ischemic transient attack
(TIA) were not excluded in the analysis, as it was con-
sidered a risk factor for major cerebrovascular events
(as well as other conditions like myocardial infarction,
atrial fibrillation, etc.). Patients who, at the last day of
observation, were alive but did not reach 1 year of fol-
low-up, were excluded from the analysis in order to
avoid overestimation of annual costs (complete follow-
up period is not possible, and patients could generally
use higher amount of resources during first months
after disease onset).
Clinical and economic outcomes estimation
The demographic and clinical characteristics of the sample
population were obtained from the clinical registry, which
collected detailed information of social status, job, clinical
and pharmacological anamnesis, status of the disease at
hospital admission. In particular, Barthel Index [23] and
NIHSS (National Institute of Health Stroke Scale) [24]
scores were collected to estimate the level of physical de-
pendency and the level of neurological deficit, respectively.
Survival analysis was conducted using the Kaplan-Meier
method, to estimate time to death and time to fatal or
non-fatal cardio-cerebrovascular event for the sample
population, over the follow period. In the analysis of time
to fatal and non-fatal event, a patient was supposed to
have a failure if resulted either dead or if he had hospital
admission with at least one of the following ICD-9 [25]
(International Statistical Classification of Diseases and
Related Health Problems, 9th Revision) diagnoses: 43X.XX
(cerebrovascular diseases), 342.XX (hemiplegia and hemi-
paresis), 410.XX, 411.XX, 413.XX, 414.XX (myocardial
infarction, angina pectoris, other ischaemic diseases),
424.XX, 426.XX, 427.XX, 428.XX (myocardial diseases,
conduction disturbances, arrhythmia and heart fail-
ure), 785.XX, 780.0X, 784.3X, 784.5X (alterations and
Table 3 Sample characteristics: clinical variables
Variable
Total patients – No (%) 800 (100%)
Type of stroke – No (%)
Ischaemic 572 (71.5%)
Haemorrhagic 96 (12.0%)
TIA (Transient ischaemic attack) 113 (14.1%)
Undetermined 19 (2.4%)
Comorbidities and risk factors – No (%)





Familiarity for CV diseases 77 (9.6%)
Previous TIA 53 (6.6%)
Atrial fibrillation 129 (16.1%)
Heart failure 56 (7.0%)
Body mass index (Kg/m2)
No (%) 592 (100.0%)
Mean (± SD) 25.1 (3.8)
Level of disability measured with Barthel Index at admission
No (%) 790 (100.0%)
Totally independent (0–20) 133 (16.8%)
Minimally dependent (21–60) 8 (1.0%)
Moderately dependent (61–90) 229 (29.0%)
Severely dependent (91–99) 184 (23.3%)
Totally dependent (100) 236 (29.9%)
Level of neurological deficit measured with National Institutes of Health Stroke Scale (NIHSS) at admission
No (%) 790 (100.0%)
No neurological deficit (NIHSS=0) 83 (10.5%)
Light neurological deficit (NIHSS=1-7) 449 (56.8%)
Moderate neurological deficit (NIHSS=8-14) 110 (13.9%)
Severe neurological deficit (NIHSS ≥15) 148 (18.7%)
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brovascular accident). Patients were censored either if
emigrated (or temporary transferred) within the observa-
tion period, or at the end of the observation period.
Economic resources consumed during the observation
period were collected from regional administrative data-
bases. For each of the patients recorded in the disease
clinical registry, healthcare interventions occurred within
the observation period were collected. We collected eco-
nomic resources which were directly attributable to the
cerebrovascular event: 1) drugs used for cardio-
cerebrovascular prevention (anti-thrombotic agents, anti-
diabetes agents, anti-hypertension agents, lipid-lowering
drugs; 2) hospitalizations due to cardio-cerebrovascular
events (according to the above mentioned classification);3) routine ambulatory procedures for stroke patients,
defined by investigators, including rehabilitation costs.
Two different cost of illness indicators were calculated:
1) the average yearly patient cost (regardless of observa-
tion time, which could be <365 days if the patient died be-
fore the end of the observation period), and 2) the cost
per patient per year, which was calculated by dividing the
overall amount of costs (sum of patient costs) during the
year after the index date by the overall time of observation
(sum of patient observation times). In addition, the aver-
age contribute of each cost component was evaluated.
Finally, two different analyses were performed to test
cost differences among homogenous groups of patients. In
the first analysis, we compare resource consumptions over
by different forms of cerebrovascular diseases (ischaemic
Figure 2 Distribution of patients according to Barthel index at hospital admission and discharge (n=667).
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level of physical disability and neurological deficit. In the
second analysis, we evaluated the relation between overall
costs and age, sex, type of stroke, level of disability, level
of neurological deficit, previous cardiovascular disease and
observation time (analysis of predictors).
Statistical analysis
Analyses of socio-demographic status of the sample, clin-
ical conditions prior to the index event, level of disease se-
verity at hospital admission, as well as survival analyses
were purely descriptive. As regards the cost analyses, two
different approaches were adopted. Univariate (parametric
and non-parametric) analysis was used to compare annualFigure 3 Distribution of patients according to NIHSS scores at hospitcosts by stroke type, physical disability, neurological def-
icit, while Generalized Linear Model (GLM) with log link
and inverse Gaussian family was used to study the relation
between costs and independent variables. This methodo-
logical approach has been extensively used in predicting
costs in recent [26-29].
Results
Analysis at 1 year
Overall, 800 (58.0%) of 1,380 patients included in the
registry were included in the analysis. Reasons of
exclusion are shown in Table 1. 272 patients (19.7%)
having a previous diagnosis of major cerebrovascular
disease, were excluded from the sample. Tables 2 and 3al admission and discharge (n=667).
Figure 4 Kaplan-Meier survival analysis to determine time to death.
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istics of the sample, respectively. The mean age was 74.9
years (SD: ±13.5) and the sample was equally distributed
between males and females (48.6% and 51.4%, respect-
ively). The majority of patients (n=572, 71.5% of overall
sample) was affected by confirmed ischaemic stroke,
while haemorrhagic stroke occurred in 96 cases (12.0%).
19 cases (2.4%), for whom it was not possible to clearly
determine the form of stroke, were defined as “undeter-
mined”. 88 (11.0%) patients were previously affected byFigure 5 Kaplan-Meier survival analysis to determine time to death omyocardial infarction. The most frequent risk factor
among the sample population was hypertension, diag-
nosed in 76.4% of patients prior to index date. 141
(17.6%) and 202 (25.3%) subjects were also affected by
diabetes and dyslipidemia, respectively. The average
length of stay of the hospitalization determining the
cerebrovascular event was 16.6 days (SD:±18.2).
At admission, 53.2% of patients showed a moderate to
severe level of disability, measured with Barthel Index
(score between 91 and 100). However, in those 667r fatal or non-fatal cardio-cerebrovascular event.
Table 4 Composition of average, per patient annual costs
Type of costs
Total costs, € (% on total costs) 7,079 (100%)
Hospital costs, € (% on total costs) 6,340 (89.5%)
Ambulatory costs, € (% on total costs) 409 (5.8%)
Specialistic visits 72 (17.6%)
Instrumental tests 72 (17.6%)
Laboratory analyses 99 (24.2%)
Rehabilitation 164 (40.1%)
Other 2 (0.5%)
Drug costs, € (% on total costs) 330 (4.7%)
Anti-thrombotic drugs 43 (13.0%)
Anti-hypertension drugs 208 (63.0%)
Anti-diabetes drugs 26 (7.9%)
Lipid-lowering drugs 53 (16.1%)
Table 5 Frequency of resource usage in the ≥30 days
survivors (n=669)
Type of resource
Hospitalization – No (%) 669 (100%)
Ambulatory care 644 (89.5%)
Anti-thrombotic drugs 516 (77.1%)
Anti-hypertension drugs 531 (79.4%)
Anti-diabetes drugs 100 (14.9%)
Lipid-lowering drugs 165 (24.7%)
Bottacchi et al. BMC Health Services Research 2012, 12:372 Page 7 of 11
http://www.biomedcentral.com/1472-6963/12/372subjects with Barthel index measured both at admission
and at discharge, a significant reduction of the disability
level was observed (Figure 2, chi-square test, p<0.001). As
regards the neurological deficit, 32.6% of patients showed
a moderate to serious level of disability. However, similarly
to physical disability, a significant improvement of neuro-
logical status was observed at the end of hospitalization
(Figure 3, chi-square test, p<0.001).
Of the 800 patients, 114 (14.3%) died during hospital
staying, while other 88 (11.0%) died within the first year
after index date. Overall, about 13 deaths per 100
patients per year occurred. Figure 4 shows survival func-
tion for the 686 patients who were discharged alive after
cerebrovascular event. In this cohort, survival probabil-
ities were 92.1% and 87.2%, at 180 days and 360 days
after the index date. Figure 5 shows the Kaplan-Meier
estimation of time to fatal or non-fatal cardio-cerebro-
vascular events. In the first 365 days following the index
date, 252 of 684 subjects included in this analysis
(36.8%) died or had cardio-cerebrovascular event. The
risk of death or non-fatal cardio-cerebrovascular acci-
dent in the first 6 months after the index date was ap-
proximately 25%.
After 1 year of observation, the overall cost per patient
was €7,079. Distribution of average costs per patients
was asymmetric, with a median value of €4,580. During
the first year of observation, the overall healthcare ex-
penditure was €5,663,259. This expenditure was gener-
ated in 231,013 overall days of follow up (about 289 days
per patient observed), resulting in €8,498 per patient per
year of observation (approximately €24.5 per patient per
day). Table 4 shows the cost composition from discharge
to year of follow-up. Hospital costs (€6,340) represent
the main driver of expenditure, accounting for 89.5% of
the total direct costs (these costs also include inpatient
rehabilitation costs, which could not be separated from
management costs for the acute event). Costs for out-
patient rehabilitation were 40.1% of the ambulatory costs
(total: €164 per patient). The average per patient cost
was sensibly different according to survival time: as
expected, patients surviving ≥ 30 days (n=669) costs
€7,531, respect to patients surviving <30 days or dead
during hospital staying (n=131; €4,770). As shown in
Table 5, the frequency of anti-thrombotic agents, anti-
hypertension drugs was above 75% among patients sur-
viving ≥30 days after the index date. In the same group,
almost all patients (96.3%) had at least an access for am-
bulatory services (diagnostic tests, laboratory analysis,
physician visits, etc.).
Analysis of variance in univariate analyses showed a sta-
tistically significant difference (p<0.0001) of costs by type of
stroke (Figure 6). This trend was also confirmed through
non-parametric tests Fischer tests, evaluating the different
distribution of cost quartiles among the groups (p<0.0001).Similar statistical results were achieved analyzing costs by
level of physical disability at hospital discharge (totally inde-
pendent: €5,192.4; minimally dependent: €5,108.9; moder-
ately dependent: €7,306.9; severely dependent: €10,461.5;
totally dependent: €12,702.4) and level of neurological def-
icit (no neurological deficit: €4,926.7; light neurological def-
icit: €7,327.3; moderate neurological deficit: €15,546.7;
severe neurological deficit: €15,204.9).
Finally, a generalized linear regression was elaborated to
study the relation between costs (dependent variable),
demographic and clinical variables (independent vari-
ables). The log-link model successfully met diagnostic
tests (Pearson correlation test: 0.6277, Pregibon link test:
0.7963, modified Hosmer and Lemeshow: 0.8811; p>0.05
values allowing analysis requirements). The modified-Park
test suggested the usage of the inverse Gaussian family
function (according to which variance is proportional to
the cube of the mean). As shown in Table 6, the general-
ized model indicates that sex, level of neurological deficit
(measured with NIHSS) and level of disability (measured
with Barthel index) affected overall annual costs. Unlike
univariate analysis, type of stroke was not found to influ-
ence annual costs. Other demographic and clinical vari-
ables (age, previous myocardial infarction, length of follow
Figure 6 Average annual costs, by type of stroke.
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patients with moderate and severe neurologic impairment
cost 105% and 96% more than patients without neurologic
impairment, and patients with moderate and high level of
disability (severely or totally dependent) cost 27% and 52%
more than patients without physical disability.
Analysis at 2 and 3 years
The analysis at 2 years included 549 patients. 655 of the
initial 1,380 (47.1%) subjects were excluded from the
analysis since they could not be observed for at least 2
years (index date prior to January 1, 2006). Most demo-
graphic (age, sex) and clinical characteristics of the sam-
ple (distribution by type of stroke, Barthel Index, NIHSS
scores) were not different from the sample observed in
1-year analysis. The overall death risk at the end of the
second year of observation was 21%, while the risk of
death or non-fatal cardio-cerebrovascular event for the
same period was 47%. The overall per patient cost in the
first two years from index date was €7,901 (median:
€5,114, Figure 7), with hospital costs remaining the main
cost driver, accounting for 84.8% of total costs.
Subjects eligible for the analysis at 3 years were 268.
As well as in the analysis at 3 years, demographic and
clinical average values and distribution remain quite
similar. Kaplan Meier survival analysis showed a risk of
death or non-fatal cardio-cerebrovascular accident of
29% and 59% at the end of year 3 from index date, re-
spectively. The overall costs during the 3 years
amounted to €8,874 (median: €5,670, Figure 7).
Discussion and conclusion
The present cost of illness analysis is an example of inte-
gration of two informative sources (clinical and adminis-
trative data) providing complementary information. Many
cost of illness studies [30-34] have been conducted using
administrative claims. Although suitable as approach forevaluating direct healthcare costs, pure administrative
database analysis shows some limitations. First, such
analyses cannot capture indirect costs (i.e. loss of product-
ivity), therefore are not suitable to conduct cost of
illness analyses in the society perspective. Second,
characterization of sample population is often poor and
based on assumptions. Both clinical and socio-
demographic information (i.e. severity of the disease, level
of disability, comorbidities, job, social status, etc.) are not
available and this makes studies from administrative data-
bases hardly usable for inferential analysis. On the other
hand, perspective, observational economic studies are
designed to clearly match objectives defined in the study
protocol. However, longitudinal, perspective studies are
time consuming and their implementation requires large
economic. In many cases, data collection is made through
questionnaires which are directly administered to the
patients. This approach is not always reliable and could
generate mistakes and incompleteness of results.
The approach used in the present study intends to over-
come the typical drawbacks of administrative database
analyses. The integration with a clinical registry allows a
detailed characterization of the patient at the index date.
The inclusion of incident patients assures homogeneous
evaluation of costs, and the characterization type of cere-
brovascular event at baseline permits to obtain informa-
tion on forms such as haemorrhagic stroke, which has
been less frequently evaluated by health economists.
Demographic and clinical characterization was also useful
to run cost prediction models. Statistical results (level of
correlation, adjusted R-squared) show similar findings of
the model elaborated by Gerzeli et. al [20] in their longitu-
dinal analysis.
Cost of stroke within the first year of occurrence is
concerning. A patient affected by first stroke episode
costs, on average, €24.5 per day. Observed daily costs
are increasingly higher for increasing level of physical
Table 6 Results of the generalized linear model analysis
Variables Exp(b) 95% Confidence interval P
valueLower limit Upper limit
Sex
Female Reference
Male 1.174949 1.057331 1.305651 0.003
Age (quartiles)
First quartile (20.3-68.1 yrs) Reference
Second quartile (68.3- 77.5 yrs) 1.016946 0.882974 1.171244 0.816
Third quartile (77.5-83.9 yrs) 0.987269 0.851009 1.145346 0.866
Fourth quartile (83.9-98.7 yrs) 0.850884 0.718406 1.007793 0.061
Type of stroke
Ischemic stroke Reference
Hemorrhagic stroke 1.009120 0.813787 1.251339 0.934
TIA 0.877714 0.741751 1.038599 0.129
Undetermined 0.812306 0.548259 1.203519 0.300
Level of neurological deficit measured with NIHSS
No neurological deficit Reference 0.991601 1.356929 0.064
Light neurological deficit 1.159971
Moderate neurological deficit 2.047076 1.390864 3.012889 0.000
Severe neurological deficit 1.960430 1.236072 3.109273 0.004
Physical disability with Barthel index
Totally independent Reference
Minimally dependent 0.909896 0.661837 1.250929 0.561
Moderately dependent 1.270401 1.096781 1.471505 0.001
Severely or totally dependent 1.519167 1.259055 1.833018 0.000
Previous myocardial infarction
No Reference
Yes 1.087153 0.903138 1.308661 0.377
Observation time (days) 0.999009 0.997970 1.000050 0.062
Number of observations = 667.
Log likelihood = −9281.635433.
AIC* = 27.87897.
BIC** = −4233.279.
* Akaike information criterion.
** Bayesian information criterion.
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costs for haemorrhagic events were the highest among
different forms of stroke, although this variable did not
explain costs variability in the regression model. Direct
costs for haemorrhagic stroke patients in the first year
after the event were quite low if compared with those of
other countries. Dodel et al., in their analysis of sub-
arachnoid hemorrhage in Germany reported an annual
direct cost of €22,482, most of which (92%) covered by
health insurance [35]. Cost composition and evolution
of overall management costs at 1, 2, 3 years suggest two
important aspects. First, inpatient management and re-
habilitation represent the main cost driver (about 90% of
direct costs at year 1). Post-event healthcare interven-
tions (pharmacological treatment and follow up visits)
do not seem requiring significant amount of resources.Second, the comparison between costs at years 1, and
costs at year 2 and 3, clearly suggested that most of the
healthcare expenditure is concentrated in the first
months after the acute event. This aspect highlights the
enormous importance, for our healthcare service, to in-
vest more in prevention. In particular, life-style modifica-
tions and pharmacological interventions on selected, at
high-risk populations should be intensified. In our ana-
lysis, we retrospectively observed the usage of certain
drugs preventing CV events in our sample population.
As example, only 41% and 15% of the sample received
an anti-thrombotic therapy and lipid-lowering treatment
before the index date, respectively.
Previous experiences of stroke cost of illness studies
showed a certain variability of results, maybe due to the
different methodological approaches adopted. However,
Figure 7 Per patient costs, at 1, 2 and 3 years from index date.
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per year of observation), however are lower, but somehow
comparable to previous findings (Gerzeli et al. [20], €6,111
for direct healthcare costs in the first 180 days after stoke),
especially considering that: 1) our sample also included
patients with TIA, consuming less resources than patients
with stroke; 2) distribution of costs is not homogeneous
over the first year, with most resources consumed during
the first months after the acute episode; 3) determination
of attributable costs is subject to expert judgment and
therefore can differ across studies. Moreover, other inter-
national studies found similar trends for long term care of
stroke patients [9]. The cost difference between cardio-
embolic stroke and TIA was also found by Winter et al.,
in their recent work [36]. The same authors also highlight
the acute stroke care as the most relevant cost contributor
in management of stroke patients.
The present study shows some limitation regarding the
assessment of rehabilitation costs, which could not be
break-downed from hospital costs through our inform-
ative sources. Therefore these costs were included in the
analyses, but we were not able to determine their impact
on the overall healthcare expenditure. The analysis of
SDO [37] (Hospital Discharge Forms) highlights that LOS
(length of stay) of certain patients was longer than 2
weeks, suggesting that those patients were likely moved
from the neurology ward to the rehabilitation ward to ini-
tiate physiotherapy programs . However, we did not have
additional information to estimate the amount of days
spent in each of the two wards. The second limitation is
due to the choice of including only costs being directly
attributable to the cerebrovascular event with high level
of evidence. As example, we included in the cost measure-
ments only post-event hospitalizations for cardio-
cerebrovascular events and evaluated drug expenditure for
therapies used in cardio-cerebrovascular prevention.
Direct costs could have been slightly underestimated;however we preferred to maintain this conservative ap-
proach rather than including costs attributable to other
underlying causes. Third, this analysis does not capture in-
direct costs, which are relevant in stroke [35], but for
which a different study approach (mainly based on per-
spective data) should be adopted.
Our analysis, focused on Region Valle d’Aosta, does
not provide any cost comparison among Italian regions.
Further research should be oriented to replicate and im-
prove this methodological approach and compare costs
by geographical area. A recent study from Frolich et al.
[38] highlights large difference of costs when different
healthcare systems are compared to each other. In this
case, cost differences may be also attributed to different
methodological approach. However, we have reason to
believe that minor differences would exist among Italian
regions, due to a quite standardized hospital care man-
agement and a similar access to medical therapies in the
different regions.
In conclusion, integrating clinical and administrative
data, whereas applicable, seems extremely powerful to
obtain reliable and useful information to support
evidence-based healthcare programs. Moreover, it per-
mits to retrospectively analyze data in a fast and not
expensive way. We believe that this approach, if further
refined, will be increasingly exploited by our policy
makers in the future.Competing interests
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